Jennifer Wittman
Psychiatric/Mental Health · Coralville, IANPI 1013564996
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,000 of the $24,720 with a category attached, or 85.0%. AbbVie accounts for 96.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $19,444 and has fallen 97.3% since, to $530 in 2025. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $136.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24K
- Novo Nordisk$130
- Alkermes, Inc.$121
- Pfizer$109
- Inspire Medical Systems, Inc.$80
- Neurocrine Biosciences, Inc.$70
- plus $363 from 15 others
What the payments were for
- Speaking & faculty fees$21,00085%
- Travel & lodging$1,1645%
- Food & beverage$2,55610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $23,847 |
| Novo Nordisk | 6 | $130 |
| Alkermes, Inc. | 1 | $121 |
| Pfizer | 7 | $109 |
| Inspire Medical Systems, Inc. | 1 | $80 |
| Neurocrine Biosciences, Inc. | 3 | $70 |
| Insulet Corporation | 1 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Bayer | 1 | $33 |
| Amgen | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Biofire Diagnostics, LLC | 1 | $20 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Medtronic | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,720 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 47 | $69,976 |
| OzempicSemaglutide | 32 | $44,374 |
| JardianceEmpagliflozin | 43 | $34,161 |
| EliquisApixaban | 39 | $32,485 |
| FarxigaDapagliflozin Propanediol | 19 | $19,737 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $14,055 |
| UbrelvyUbrogepant | 13 | $13,508 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $10,889 |
| TrulicityDulaglutide | 11 | $10,576 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $7,255 |
| LinzessLinaclotide | 11 | $6,320 |
| CreonLipase/Protease/Amylase | 11 | $4,084 |
| Pantoprazole Sodium | 183 | $3,988 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $3,587 |
| Entacapone | 11 | $2,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Linzess, Creon, Synthroid | $23,847 | $95,71699 claims |
| Novo NordiskOzempic | $130 | $44,37432 claims |
| PfizerEliquis | $109 | $32,48539 claims |
| Lilly USA, LLCTrulicity | $16 | $10,57611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Coralville
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
- Amy MorinCedar Rapids$24K
- Jenna BerendzenCedar Falls$22K
- Daniel WesemannDavenport$15K
- Melissa KonkenSioux City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.